All In Biotech

Drug Trial Radar · NCT06730347

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Jul 2027

Study completion Dec 2027

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.

Conditions

  • Platinum-resistant Ovarian Cancer
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Clear Cell Adenocarcinoma of Ovary
  • Clear Cell Adenocarcinoma of Vulva
  • Clear Cell Adenocarcinoma of Vagina
  • Clear Cell Adenocarcinoma of Cervix
  • Clear Cell Adenocarcinoma of Uterus
  • Clear Cell Adenocarcinoma of Fallopian Tube
  • Clear Cell Adenocarcinoma of Peritoneum
  • Endometrial Cancer

Interventions

  • LorigerlimabBiological

    Bispecific DART protein binding PD-1 and CTLA-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigatorTime frame: Throughout the study up to approximately 2 years

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Recruiting

  • Ochsner MD Anderson Cancer Center

    New Orleans, Louisiana · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • West Penn Allegheny Health

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center

    Houston, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • Wisconsin Institute Medical Research- UW Cancer Connect

    Madison, Wisconsin · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • McGill University

    Montreal, Quebec, Canada · Recruiting

  • Yonsei University Health System Severance Hospital

    Seoul, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Hospital Bundang Hospital

    Seongnam-si, Gyeonnggi-Do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.